Is there a role for autologous hematopoietic stem‑cell transplantation in acute myeloid leukemia?

Role of Autologous HSCT in AML

Autologous HSCT has a limited but specific role in AML consolidation therapy, primarily as an alternative option for favorable- and intermediate-risk cytogenetics when allogeneic transplant is not available, though it does not improve overall survival compared to chemotherapy alone. 1

Risk-Stratified Recommendations

Favorable-Risk AML

• Autologous HSCT is considered an alternative option for patients with favorable-risk cytogenetics (CBF translocations without KIT mutations, NPM1-mutated/FLT3-wild type) who achieve first complete remission 1
• Outcomes after autologous HSCT are at least as good as postremission chemotherapy, with lower relapse rates than chemotherapy alone, though without demonstrable improvement in overall survival 1
• The European LeukemiaNet guidelines note that autologous HSCT may offer an advantage in specific subsets of favorable-risk AML 1
• Recent data show 5-year disease-free survival of 76% in favorable-risk patients, with particularly excellent results in CBF leukemia (72-100% 10-year DFS) 2

Intermediate-Risk AML

• The role of autologous HSCT in intermediate-risk AML is diminishing due to improvements in allogeneic transplantation and expanded donor availability 1
• The NCCN consensus states that autologous HSCT should not be a recommended consolidation therapy outside clinical trials for intermediate-risk disease 1
• Comparable 5-year DFS rates (41-45%) have been reported between autologous HSCT and high-dose cytarabine consolidation in intermediate-risk patients 1
• Allogeneic HSCT offers superior outcomes with lower relapse rates in this population 1

High-Risk/Adverse Cytogenetics

• Autologous HSCT cannot be recommended for patients with high-risk cytogenetics 1
• Allogeneic HSCT from a matched related donor is the treatment of choice for unfavorable cytogenetics in first complete remission 1

Critical Factors Influencing Outcomes

Minimal Residual Disease (MRD) Status

• Pre-transplant MRD status is the most important factor determining eligibility and predicting outcomes after autologous HSCT 3
• MRD-negative status before autologous HSCT is associated with significantly better outcomes 4, 3
• In CBF leukemia specifically, autologous HSCT provides excellent results (72% 10-year DFS) even in MRD-positive patients 2

Age Considerations

• Advanced age is not an absolute contraindication for autologous HSCT 3
• Young patients (<40 years) with good- to intermediate-risk molecular cytogenetics and limited CD34+ stem cell doses show particularly favorable outcomes (83.4% 3-year DFS) 4

Stem Cell Dose

• Higher doses of CD34+ stem cells (≥4.5 × 10⁶/kg) are associated with higher relapse rates and should be avoided 4, 2
• Limited stem cell doses appear to provide better disease control 4

Comparative Outcomes

Versus Chemotherapy

• Meta-analysis demonstrates that autologous HSCT provides significantly lower relapse rates (OR = 0.49) compared to chemotherapy consolidation 5
• Superior disease-free survival (OR = 1.37) and relapse-free survival (OR = 2.78) with autologous HSCT versus chemotherapy 5
• No difference in overall survival between autologous HSCT and chemotherapy when studies are pooled (OR = 1.12) 5
• The lack of OS benefit despite lower relapse rates is attributed to higher treatment-related mortality in older studies, though this has improved significantly in the modern era 6

Versus Allogeneic HSCT

• Allogeneic HSCT demonstrates lowest relapse rates due to graft-versus-leukemia effect 1
• In secondary AML, allogeneic HSCT in first CR shows better 5-year outcomes (44.5% OS, 39.9% LFS) compared to autologous HSCT (30% OS, 20.5% LFS), though differences did not reach statistical significance for OS 7
• Higher non-relapse mortality with allogeneic HSCT is counterbalanced by lower relapse rates compared to autologous HSCT 7

Common Pitfalls and Caveats

• Do not offer autologous HSCT to patients with adverse cytogenetics – outcomes remain dismal and allogeneic transplant is strongly preferred 1
• Avoid high CD34+ stem cell doses – paradoxically associated with worse outcomes, likely due to increased tumor cell contamination 4, 2
• Do not use autologous HSCT as routine consolidation for intermediate-risk AML outside clinical trials – allogeneic options should be prioritized 1
• Ensure MRD assessment before proceeding – MRD-positive status significantly worsens prognosis and may warrant alternative approaches 4, 3
• The greatest concern with autologous HSCT remains early relapse, which occurs in approximately 39-53% of patients 8, 3

Current Clinical Context

The role of autologous HSCT has evolved considerably with improvements in supportive care reducing transplant-related mortality to levels comparable to standard consolidation chemotherapy 6. However, widespread adoption of haploidentical and unrelated donor allogeneic transplantation has further marginalized the role of autologous HSCT 1. The procedure remains most relevant for favorable-risk patients who achieve deep remissions (MRD-negative) and lack suitable allogeneic donors 1, 3, 2.